
Mladen Vassilev Tzvetkov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7980609/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Amino acids in transmembrane helix 1 confer major functional differences between human and mouse orthologs of the polyspecific membrane transporter OCT1. Journal of Biological Chemistry, 2022, 298, 101974.	3.4	6
2	Cloning and Functional Characterization of Dog OCT1 and OCT2: Another Step in Exploring Species Differences in Organic Cation Transporters. International Journal of Molecular Sciences, 2022, 23, 5100.	4.1	1
3	Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport. Frontiers in Pharmacology, 2021, 12, 674559.	3.5	11
4	Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. Frontiers in Pharmacology, 2021, 12, 688950.	3.5	14
5	OCT1 Polyspecificity—Friend or Foe?. Frontiers in Pharmacology, 2021, 12, 698153.	3.5	5
6	Variability and Heritability of Thiamine Pharmacokinetics With Focus on OCT1 Effects on Membrane Transport and Pharmacokinetics in Humans. Clinical Pharmacology and Therapeutics, 2020, 107, 628-638.	4.7	18
7	Pharmacokinetic Drugâ€Ðrug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. Journal of Clinical Pharmacology, 2020, 60, 312-323.	2.0	10
8	Stereoselective cell uptake of adrenergic agonists and antagonists by organic cation transporters. Biochemical Pharmacology, 2020, 171, 113731.	4.4	19
9	A double-Flp-in method for stable overexpression of two genes. Scientific Reports, 2020, 10, 14018.	3.3	6
10	Inherited and Acquired Determinants of Hepatic CYP3A Activity in Humans. Frontiers in Genetics, 2020, 11, 944.	2.3	14
11	Differences in Metformin and Thiamine Uptake between Human and Mouse Organic Cation Transporter 1: Structural Determinants and Potential Consequences for Intrahepatic Concentrations. Drug Metabolism and Disposition, 2020, 48, 1380-1392.	3.3	22
12	<scp>OCT</scp> 1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil. Clinical Pharmacology and Therapeutics, 2019, 105, 190-200.	4.7	31
13	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. Journal of Medicinal Chemistry, 2019, 62, 9890-9905.	6.4	24
14	An in vitro study on interaction of anisodine and monocrotaline with organic cation transporters of the SLC22 and SLC47 families. Chinese Journal of Natural Medicines, 2019, 17, 490-497.	1.3	5
15	Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A. Frontiers in Pharmacology, 2019, 10, 1297.	3.5	12
16	Assay Conditions Influence Affinities of Rat Organic Cation Transporter 1: Analysis of Mutagenesis in the Modeled Outward-Facing Cleft by Measuring Effects of Substrates and Inhibitors on Initial Uptake. Molecular Pharmacology, 2018, 93, 402-415.	2.3	17
17	Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable <i>OCT1</i> Deficiency. Clinical Pharmacology and Therapeutics, 2018, 103, 868-878.	4.7	56
18	The CTLA-4 rs231775 GG genotype is associated with favorable 90-day survival in Caucasian patients with sepsis. Scientific Reports, 2018, 8, 15140.	3.3	13

#	Article	IF	CITATIONS
19	The FER rs4957796 TT genotype is associated with unfavorable 90-day survival in Caucasian patients with severe ARDS due to pneumonia. Scientific Reports, 2017, 7, 9887.	3.3	18
20	Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families. Biological Chemistry, 2017, 398, 237-249.	2.5	28
21	Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine. PLoS ONE, 2017, 12, e0189521.	2.5	32
22	OCT1 mediates hepatic uptake of sumatriptan and lossâ€ofâ€function <i>OCT1</i> polymorphisms affect sumatriptan pharmacokinetics. Clinical Pharmacology and Therapeutics, 2016, 99, 633-641.	4.7	71
23	Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. Pain, 2016, 157, 2467-2475.	4.2	45
24	Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. Genome Medicine, 2016, 8, 119.	8.2	10
25	Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1. Genome Medicine, 2015, 7, 56.	8.2	77
26	The CD14 rs2569190 TT Genotype Is Associated with an Improved 30-Day Survival in Patients with Sepsis: A Prospective Observational Cohort Study. PLoS ONE, 2015, 10, e0127761.	2.5	16
27	High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors. Pharmacogenomics, 2015, 16, 1605-1619.	1.3	7
28	Genetic Polymorphisms in Endothelin-1 as Predictors for Long-Term Survival and the Cardiac Index in Patients Undergoing On-Pump Cardiac Surgery. PLoS ONE, 2015, 10, e0131155.	2.5	3
29	The Poorly Membrane Permeable Antipsychotic Drugs Amisulpride and Sulpiride Are Substrates of the Organic Cation Transporters from the SLC22 Family. AAPS Journal, 2014, 16, 1247-1258.	4.4	82
30	Does the haplotype Met408-Del420, which was apparently predictive for imatinib efficacy, really exist and how strongly may it affect OCT1 activity?. Blood, 2014, 123, 1427-1429.	1.4	10
31	Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochemical Pharmacology, 2013, 86, 666-678.	4.4	168
32	Lithium enhances CRTC oligomer formation and the interaction between the CREB coactivators CRTC and CBP — Implications for CREB-dependent gene transcription. Cellular Signalling, 2013, 25, 113-125.	3.6	15
33	Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron. Pharmacogenomics Journal, 2012, 12, 22-29.	2.0	128
34	The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochemical Pharmacology, 2012, 83, 1427-1434.	4.4	56
35	Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of <i>ERCC1</i> polymorphisms. Pharmacogenomics, 2011, 12, 1417-1427.	1.3	48
36	Genetically Polymorphic OCT1: Another Piece in the Puzzle of the Variable Pharmacokinetics and Pharmacodynamics of the Opioidergic Drug Tramadol. Clinical Pharmacology and Therapeutics, 2011, 90, 143-150.	4.7	126

#	Article	IF	CITATIONS
37	Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies. Pharmacogenomics, 2010, 11, 449-457.	1.3	25
38	Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochemical Pharmacology, 2009, 78, 45-53.	4.4	44
39	Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenetics and Genomics, 2008, 18, 495-506.	1.5	68
40	Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine. Gene, 2007, 386, 52-62.	2.2	65